Davide Melisi
University of Verona(IT)Azienda Ospedaliera Universitaria Integrata Verona(IT)
Publications by Year
Research Areas
Pancreatic and Hepatic Oncology Research, Cancer Research and Treatments, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study(2020)1,533 cited
- → Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study(2023)612 cited
- → NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial(2023)396 cited
- → Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy(2004)346 cited
- → LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis(2008)315 cited
- → Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib